Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391506 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL26144 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL931394 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL246013 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL28795866 | 0.96 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL27515670 | 0.96 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL26629020 | 0.94 | DNM1 (0.44) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL9302688 | 0.90 | ADRB2 (0.38) | DNM1CA1CA2CA9TSHR | |
| SCHEMBL2701156 | 0.88 | ALDH1A1 (0.51) | LPAR1LPAR3LPAR2 | |
| SCHEMBL27503005 | 0.86 | ADRB2 (0.35) | DNM1CA1CA2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4370135-A2 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Generation Bio Co. (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4351533-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Generation Bio Co. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023239756-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023077156-A1 | MODIFIED MRNA THERAPEUTICS | SHATTUCK LABS, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023287861-A2 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2022261101-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-2405921-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION | Protiva Biotherapeutics Inc. (CA) | 2012-01-18 | — | — | EP | claimed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | claimed |
| JP-4796062-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| WO-2011038160-A2 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | WO | claimed |
| WO-2011011447-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-27 | — | — | WO | claimed |
| WO-2010105372-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS C VIRUS EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-23 | — | — | WO | claimed |
| WO-2010083615-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-07-29 | — | — | WO | claimed |
| EP-1766035-A1 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2007-03-28 | — | — | EP | claimed |
| WO-2006007712-A1 | METHODS COMPRISING POLYETHYLENE GLYCOL-LIPID CONJUGATES FOR DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-26 | — | — | WO | claimed |
| WO-2005121348-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |